Sidoti Downgrades Prestige Consumer Healthcare (NYSE:PBH) to Neutral

Prestige Consumer Healthcare (NYSE:PBH) was downgraded by equities researchers at Sidoti from a “buy” rating to a “neutral” rating in a research note issued on Monday, Marketbeat Ratings reports. They presently have a $90.00 price target on the stock. Sidoti’s price target points to a potential upside of 6.82% from the company’s current price.

A number of other equities analysts have also weighed in on PBH. DA Davidson restated a “buy” rating and issued a $95.00 price objective on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. Jefferies Financial Group reissued a “hold” rating and set a $76.00 price target (up previously from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $85.25.

Prestige Consumer Healthcare Stock Performance

Shares of PBH opened at $84.25 on Monday. Prestige Consumer Healthcare has a 12-month low of $57.95 and a 12-month high of $86.36. The company has a market cap of $4.16 billion, a PE ratio of 20.50, a price-to-earnings-growth ratio of 2.37 and a beta of 0.49. The company has a current ratio of 3.56, a quick ratio of 2.10 and a debt-to-equity ratio of 0.61. The stock has a 50-day moving average price of $77.27 and a 200-day moving average price of $72.19.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.09. The business had revenue of $283.79 million during the quarter, compared to analyst estimates of $282.09 million. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The company’s revenue was down .9% on a year-over-year basis. During the same period in the prior year, the business posted $1.07 earnings per share. As a group, equities analysts forecast that Prestige Consumer Healthcare will post 4.44 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, SVP Mary Beth Fritz sold 9,885 shares of the firm’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $81.97, for a total value of $810,273.45. Following the completion of the transaction, the senior vice president now directly owns 18,835 shares in the company, valued at $1,543,904.95. This trade represents a 34.42 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Ronald M. Lombardi sold 10,875 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total transaction of $898,275.00. Following the sale, the chief executive officer now owns 320,952 shares of the company’s stock, valued at approximately $26,510,635.20. The trade was a 3.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 38,810 shares of company stock valued at $3,187,300 over the last three months. 1.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of PBH. Franklin Resources Inc. lifted its stake in Prestige Consumer Healthcare by 4.3% in the 3rd quarter. Franklin Resources Inc. now owns 21,585 shares of the company’s stock valued at $1,513,000 after buying an additional 894 shares in the last quarter. Sanctuary Advisors LLC boosted its stake in shares of Prestige Consumer Healthcare by 11.0% in the third quarter. Sanctuary Advisors LLC now owns 17,248 shares of the company’s stock worth $1,244,000 after acquiring an additional 1,715 shares during the last quarter. Coldstream Capital Management Inc. purchased a new stake in shares of Prestige Consumer Healthcare during the third quarter worth approximately $205,000. Geode Capital Management LLC raised its stake in Prestige Consumer Healthcare by 4.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company’s stock valued at $95,678,000 after purchasing an additional 50,961 shares during the last quarter. Finally, M&T Bank Corp lifted its holdings in Prestige Consumer Healthcare by 23.8% in the 3rd quarter. M&T Bank Corp now owns 4,594 shares of the company’s stock valued at $331,000 after purchasing an additional 882 shares in the last quarter. 99.95% of the stock is owned by institutional investors and hedge funds.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.